Oncos Therapeutics granted Orphan Drug Designation for CGTG-102 by FDA and EMA

September 15th, 2013. Helsinki, Finland - Oncos Therapeutics, the clinical stage biotech company developing next generation oncolytic viruses, today announced the appointment professor Hani Gabra, MD, PhD, in its Clinical Advisory Board (CAB).

"We are very grateful to have professor Gabra, a leading expert in translational medicine in ovarian cancer, supporting our clinical development", says Frans Wuite, MD, President and CEO of Oncos. "Ovarian cancer is the fifth leading cause of cancer death in women, with a real unmet medical need, and based on our phase I data we believe our products can make a difference. The expertise of professor Gabra will be instrumental in our further progress."

Professor Gabra is Head of Medical Oncology, and Director of the Ovarian Cancer Action Research Centre at Imperial College London, as well as Lead Clinician for Cancer Clinical Trials and Honorary Consultant Medical Oncologist at Imperial College Healthcare NHS Trust. Professor Gabra is also President of the European Translational Ovarian Cancer Network (EUTROC). His research interests span bench to bedside, include tumour suppressor biology, platinum resistance, and the conduct of translational proof of concept clinical trials of novel targeted agents.

About Oncos Therapeutics

Oncos Therapeutics Ltd is a privately owned, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapy products for solid tumors. The company's lead investor is HealthCap, one of the largest specialized providers of venture capital within life sciences in Europe. Oncos is headquartered in Helsinki, Finland and has an office in Switzerland. For more information about Oncos, please visit www.oncos.com.